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ABSTRACT
The title compound (E)-1-{4-[bis(4-methoxyphenyl)methyl]piperazin-1-yl}-3-(4-chloro- phenyl)prop-2-en-1-one (C28H29ClN2O3,
Mr = 476.98) (5) was synthesized and studied by the single crystal X-ray diffraction method. Its structure was confirmed by
1H NMR, 13C NMR, HRMS and X-ray single crystal structure determination. Compound 5 crystallized in the monoclinic system,
space group P21/c with a = 10.392(2), b = 7.9180(16), c = 30.474(6) Å, â = 97.78(3) °, V = 2484.4(9) Å
3, Z = 4, Dc = 1.275 g cm–3, F(000) =
1008, µ = 0.186 mm–1, MoKá radiation (ë = 0.71073 Å), R = 0.0692 and wR = 0.1469 for 2046 observed reflections with I < 2ó(I). The
title compound was screened for the anti-ischaemic activity in vivo. The results showed that compound 5 significantly prolonged
the survival time of mice subjected to acute cerebral ischaemia at all doses tested and exhibited potent neuroprotective activity.
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1. Introduction
In China, stroke is the second-highest cause of mortality in all
diseases. Particularly, ischaemic strokes account for 60–80 % of
these strokes. With the rapid increase of aging population in
China, stroke has become a critical cause for the health of the old,
and stroke is becoming a major burden facing the government
and health providers.1–6 Therefore, there is an urgent need of
effective neuroprotective agents to treat stroke-related brain
damage.
We reported the syntheses of novel cinnamide derivatives
containing bis(4-fluorophenyl)methyl moiety starting from
commercially available materials. Previous work suggested that
cinnamide scaffold often affords neuroprotective compounds.7
The reaction of cinnamic acid chloride with 1-[bis(4-methoxy-
phenyl)methyl]piperazine in the presence of triethylamine in
dichloromethane at room temperature afforded the correspond-
ing new cinnamide derivative with a total yield of 73.5 %
(Scheme 1), which was expected to be a potent neuroprotective
agent. Cinnamic acids are one of the key intermediates for the
synthesis of this series of compounds, which are usually obtained
by the Perkin reaction,8 the Knoevenagel condensation,9 the
Claisen condensation,10 and the Heck reaction.11 In this context,
we chose a modification of the procedure of a literature method.7
In this article, we present our results on the synthesis, crystal




2.1. Materials and Instruments
All chemicals, reagents, and solvents for synthesis of the com-
pound were commercially available and used without further
purification. Melting points were determined on an electro-
thermal digital apparatus model WRR-401 (Shanghai, China)
without correction. 1H NMR and 13C NMR spectra were
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Scheme 1
Synthesis route of the title compound 5.
recorded on a Bruker ACF-300 MHz instrument (Bruker) with
CDCl3 as the solvent and tetramethylsilane as an internal
standard (chemical shifts are expressed as d values, J in hertz).
High-resolution mass spectra (HRMS) were recorded on a
MALDI Micro MX instrument (Waters).
2.2. (E)-1-{4-[bis(4-methoxyphenyl)methyl]piperazin-1-yl}-
3-(4-chlorophenyl)prop-2-en-1-one (5).
The synthetic route of the title compound is illustrated in
Scheme 1 and is based on a modification of a procedure in the
literature7. Intermediate 1-[bis(4-methoxyphenyl)- methyl]pipe-
razine 2 was synthesized from bis(4-methoxyphenyl)metha-
none 1 according to the literature.12
(E)-3-(4-chlorophenyl)acrylic acid 4 was prepared from
4-chlorobenzaldehyde 3 by the Knoevenagel reactions.13 The
title compound (E)-1-{4-[bis(4-methoxyphenyl)methyl]pi-
perazin-1-yl}-3-(4-chlorophenyl)prop-2-en-1-one 5 was obtained
as follows: thionyl chloride (2 mL) and piperadine (1 drop) were
added to a stirred solution of (E)-3-(4-chlorophenyl)acrylic
acid (4, 4 mmol) in dichloromethane (15 mL) at room tempera-
ture. The reaction mixture was stirred at ambient tempera-
ture for 6 hours. After completion, the solvent was removed
under reduced pressure. The residue was dissolved in acetone
(15 mL) and reacted with the solution of 1-[bis(4-methoxy-
phenyl)methyl]piperazine (2, 6 mmol) and triethylamine (5 mL)
in dichloromethane (30 mL). After being stirred for 12 hours at
room temperature, the solvent was removed under reduced
pressure. The residue was purified by silica gel column chroma-
tography using ethyl acetate/hexane (V/V 2:1) as mobile phase to
afford target compound 5 as a white solids (1.402 g, 74 %), m.p.
114.2–116.0 °C.
dH (300 MHz, CDCl3): 2.39 (4H, m, N(CH2)2), 3.52 (4H, m,
CON(CH2)2), 3.76 (6H, s, 2CH3O), 4.18 (1H, s, CH(Ph)2), 6.77
(1H, d, J 15 Hz, = CHCO), 6.78–7.43 (12H, m, Ar-H), 7.56 (1H, d,
J 15.3 Hz, Ph-CH=,); dC (75 MHz, CDCl3): 42.3, 46.0, 52.0, 55.2,
74.5, 114.0, 117.7, 128.9, 129.0, 133.8, 134.2, 135.4, 141.2, 158.7,
165.0; HRMS (ESI, m/z): Calcd. for C28H29ClN2NaO3 [M + Na]
+
499.1764. Found: 499.1753.
Single crystals suitable for X-ray diffraction were obtained by
slow evaporation from an ethanol solution of the title compound
at room temperature.
2.3. X-ray Crystal Structure Determination
A colourless single crystal of the title compound (0.20 mm ×
0.10 mm × 0.10 mm) was selected and mounted on the top of a
glass fibre. Diffraction data was collected on an Enraf-Nonius
CAD4/PC four-circle diffractometer equipped with a graphite-
monochromatic MoKa radiation (l = 0.71073 Å) using an w/2q
scan mode in the range of 1.35 £ q £ 25.38 ° (0 £ h £ 12, 0 £ k £ 9,
–36 £ l £ 36) at 293(2) K. A total of 4840 reflections were collected,
of which 4571 were independent (Rint = 0.0551) and 2046 were
observed with I < 2s(I). The structure was solved by direct
methods and refined against F2 by full-matrix least-squares
using SHELXTL-97.14 The nonhydrogen atoms were located in
successive difference Fourier synthesis. The hydrogen atoms
were added theoretically and riding on the concerned atoms.
The final refinement gave R = 0.0692, wR = 0.1469 (w =
1/[s 2(F0
2) + (0.0700P)2], where P = (F0
2 + 2Fc
2)/3), S = 1.004,
(Dr)max = 0.180, (Dr)min = –0.234 e/ Å
3 and (D /s)max < 0.001.
3. Results and Discussion
As shown in Scheme 1, the target cinnamide compound 5 was
readily synthesized by coupling the corresponding cinnamic
acid chloride with 1-[bis(4-methoxyphenyl)- methyl] piperazine
at room temperature with a total yield of 74 %. The structure of
the product was characterized with 1H NMR, 13C NMR and
HRMS. The structure of compound 5 was finally confirmed
utilizing single-crystal X-ray structure determination.
The molecular structure of the title compound with atomic
numbering is shown in Figs 1 and 2 and depict the molecular
packing in the unit cell. The selected bond distances, bond an-
gles and torsion angles are listed in Table 1, and the correspond-
ing lengths and angles of hydrogen bonds are given in Table 2.
Within the molecule, the bond length of C(7)–C(8) is 1.314(6) Å,
shorter than that of typical C=C(1.34 Å),15 due to the aromatic
conjugation; while the single bond lengths of C(9)–N(1),
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Figure 1 Perspective view of (E)-1-{4-[bis(4-methoxyphenyl)methyl]piperazin-1-yl}-3-(4- chlorophenyl)prop-2-en-1-one with the atom numbering
scheme. Displacement ellipsoids are drawn at the 70 % probability level. Dashed lines indicate intramolecular hydrogen bonds.
C(6)–C(7) and C(8)–C(9) are 1.346(5), 1.462(6) and 1.473(6) Å,
respectively, significantly shorter than the typical C(sp2)–N
(1.426 Å)16 and C–C (1.53 Å) due to the same reason, showing a
large conjugated system among the carbonyl group, ethene
bond, and the benzene ring.
The molecule exists in an E configuration with respect to the
C7=C8 ethene bond [1.314(6)]. The piperazine ring adopts a
chair conformation with puchering parameters Q = 0.578(4) Å,
theta = 169.7(4) ° , phi = 8(3) ° . In the title compound, the mole-
cule contains three essentially planar phenyl rings: atoms of
C(1)–C(6) form the 4-chlorophenyl plane (I), C(15)–C(20) generate
the 4-methoxyphenyl plane (II) and C(22)–C(27) yield the other
4-methoxyphenyl plane (III). The planes II and III form dihedral
angles of 83.6 (2) ° and 76.4 (2) ° , respectively, with the 4-chloro-
phenyl ring (I). The two 4-methoxyphenyl rings are inclined at
an angle of 67.2 (2)°  with respect to one other.
There are two weak intramolecular hydrogen bonds,
C(7)–H(7A)···O(1) and C(13)–H(13A)···O(1), forming five-
membered rings. At the same time, intermolecular hydrogen
bonds are also present, as shown in Table 2. Atom C(1) in the
molecule acts as a donor, via the H(1A) atom, to the O(1) of an
adjacent molecule (symmetry code: 1–x, –y, 1–z). These interaction
forces forces determine the three-dimensional structure.
4. Anti-ischaemic Activity
The anti-ischaemic activity of the title compound 5 was tested
using bilateral common carotid artery occlusion.17 Kunming
mice of both sexes were randomly divided into groups (10 mice
per group). The title compound was dissolved in aqueous 0.5 %
sodium carboxy methyl cellulose (CMCNa) solution before use
and administered intraperitoneally (i.p.). Nimodipine was i.p.
treated with 80 mg kg–1 as a positive control. The negative control
group received normal saline (NS) in the same volume as other
groups. All groups were given drugs twice a day for 3 days. Sixty
minutes after the last administration, all mice were anaesthe-
tized with ether. All groups underwent the operation for
common carotid artery and vagus nerves ligation.18 Then the
survival time of mice were recorded and given in Table 3.
As shown in Table 3, the title compound 5 was shown to signifi-
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Figure 2 Part of the crystal structure of (E)-1-{4-[bis(4-methoxyphenyl)methyl]-piperazin-1-yl}-3-(4-chlorophenyl)prop-2-en-1-one showing inter-
molecular hydrogen bonds.
Table 1 Selected bond lengths/Å and angles/° for C28H29ClN2O3.
Cl-C(3) 1.756(4) C(9)-N(1)-C(10) 127.4(4)
O(1)-C(9) 1.233(5) C(18)-O(2)-C(21) 118.8(4)
N(1)-C(9) 1.346(5) C(25)-O(3)-C(28) 117.4(3)
O(2)-C(18) 1.377(4) O(1)-C(9)-N(1) 120.5(4)
O(2)-C(21) 1.397(5) O(1)-C(9)-C(8) 121.0(4)
N(2)-C(12) 1.460(5) N(1)-C(9)-C(8) 118.5(4)
N(2)-C(14) 1.480(5) N(2)-C(14)-C(15) 109.5(3)
O(3)-C(25) 1.382(4) C(22)-C(14)-C(15) 110.9(3)
O(3)-C(28) 1.408(5) C(6)-C(7)-C(8)-C(9) 175.1(4)
C(6)-C(7) 1.462(6) C(7)-C(8)-C(9)-O(1) –9.1(7)
C(7)-C(8) 1.314(6) C(7)-C(8)-C(9)-N(1) 171.7(4)
C(14)-C(15) 1.526(5) C(21)-O(2)-C(18)-C(17) 8.8(6)
N(2)-C(14)-C(22)-C(27) –43.5(5)
C(28)-O(3)-C(25)-C(26) –5.1(6)
Table 2 Hydrogen bond lengths/Å and angles/° for C28H29ClN2O3.
D–H...A d(D–H) d(H...A) d(D···A) D–H...A, deg
C1–H1A...O1i 0.93 2.34 3.118(6) 141
Symmetry codes: (i) 1–x, –y, 1–z.
Table 3 Effect of the title compound 5 on survival time of mice subjected to bilateral common carotid artery ligation.
Compound Survival time/min
400 mg kg–1 200 mg kg–1 100 mg kg–1 50 mg kg–1 25 mg kg–1 12.5 mg kg–1 6.25 mg kg–1
Compound 5 14.83 ± 0.42 a 14.56 ± 0.38 a 14.62 ± 1.89 a 14.30 ± 1.98 a 10.67 ± 1.52 a 8.67 ± 1.12 a 8.92 ± 1.93 a
NS 2.04 ± 0.61
Nimodipine 3.52 ± 1.04 a
a = P < 0.05, compared with NS.
cantly prolong the survival time of mice subjected to acute
cerebral ischemia and decrease the mortality rate at all doses
tested, which indicate that the title compound 5 exhibits the
potent neuroprotective activity.
5. Conclusion
The title compound 5 was synthesized via a facile approach
and the structure assignment was supported by 1H NMR data,
13C NMR, HRMS and crystallographic studies. In the prelimi-
nary screening of the anti-ischaemic activity study, the title com-
pound 5 was shown to significantly prolong the survival time of
mice subjected to acute cerebral ischaemia and decrease the
mortality rate at all doses tested, which suggest that the title
compound 5 exhibits the potent neuroprotective activity.
Supplementary Material
X-ray crystallography data of (E)-1-{4-[bis(4-methoxy-
phenyl)methyl]piperazin-1-yl}-3-(4- chlorophenyl)prop-
2-en-1-one has been deposited with the Cambridge Crystallo-
graphic Data Centre (CCDC) and can be obtained free of charge
on request at http://www.ccdc.cam.ac.uk/conts/retrieving.
html or from the Cambridge Crystallographic Data Centre
(CCDC), 12 Union Road, Cambridge CB2 1EZ, UK; fax:.
+44(0)1223-336033; e-mail: deposit@ccdc.cam.ac.uk, quoting
the CCDC number, 921041. The IR, MS and NMR spectra of this
compound are also provided with supplementary material.
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